B. Law, M. P. , M. A. Gleadle-r, and . I. King-l, Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin, Journal of Pharmacy and Pharmacology, vol.155, issue.5, pp.289-94, 1984.
DOI : 10.1111/j.2042-7158.1984.tb04376.x

H. K. Mahlberg-p, A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae), American Journal of Botany, vol.91, pp.966-975, 2004.

V. Seutin, . J. Scuvee-moreau, and . Quertemont-e, Regard croisé sur le cannabis, Ed. Mardagon, issue.18, p.279, 2010.

M. S. and T. K. Abu-shaar, Molecular characterization of a peripheral receptor for cannabinoids, Nature, vol.365, pp.61-65, 1993.

L. Hanus, Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids, Medicinal Research Reviews, vol.2, issue.Suppl 3, pp.213-71, 2009.
DOI : 10.1002/med.20135

C. L. Hecketsweiler-c, Le Sativex, médicament à base de cannabis, 2014.

N. Tourneur, Le cannabis thérapeutique arrive en France, Le quotidien du pharmacien, vol.3059, issue.28, pp.5-8, 2014.

M. R. and P. L. Gallily-r, Cannabidiol: an overview of some pharmacological aspects by. Department of Medicinal Chemistry and Natural Products, Israel. J. Clin. Pharmacol, vol.42, pp.11-19, 2002.

S. E. Sallan, . E. Zinberg-n, and . Frei-e, Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy, New England Journal of Medicine, vol.293, issue.16, pp.795-97, 1975.
DOI : 10.1056/NEJM197510162931603

R. F. Machado, S. S. De-cassia-haiek, R. M. Oliveira-l, and S. D. Da, Therapeutic use of cannabis sativa on chemotherapyinduced nausea and vomiting among cancer patients : systematic reveiw and meta-analysis, 2008.

J. J. Manzanares and . Carrascosa-a, Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes, Current Neuropharmacology, vol.4, issue.3, pp.239-57, 2006.
DOI : 10.2174/157015906778019527

H. R. Zajicek-j, Therapeutic potential of cannabis in pain medicine, Oxford Journals, vol.101, pp.59-68, 2008.

K. M. Wippermann-s, Cannabinoids against pain : Efficacy and strategies to reduce psychoactivity : a clinical perspective, Expert Opin Investing drugs, vol.18, issue.38, pp.125-158, 2009.

F. Grotenhermen, Pharmacokinetics and Pharmacodynamics of Cannabinoids, Clinical Pharmacokinetics, vol.134, issue.4, 2003.
DOI : 10.2165/00003088-200342040-00003

. D. Gieringer, Cannabis ???Vaporization???, Journal of Cannabis Therapeutics, vol.155, issue.3-4, pp.153-70, 2001.
DOI : 10.1007/BF02244207

R. Noyes, A. T. Brunk-s, and . Canter-a, The analgesic properties of delta-9-tetrahydrocannabinol and codeine, Clinical Pharmacology & Therapeutics, vol.18, issue.1, pp.84-89, 1975.
DOI : 10.1002/cpt197518184

M. E. Lynch and . J. Clark-a, Cannabis Reduces Opioid Dose in the Treatment of Chronic Non-Cancer Pain, Journal of Pain and Symptom Management, vol.25, issue.6, pp.496-98, 2003.
DOI : 10.1016/S0885-3924(03)00142-8

C. P. Musty-r, R. J. Tillery-w, and . G. Pertwee-r, The perceived effects of smoked cannabis on patients with multiple sclerosis, Eur. Neurol, vol.38, issue.44, pp.44-48, 1997.

U. Hagenbach, . Ghafoor-n, L. S. Brenneisen-r, . Mäder-m, . G. Pertwee-r et al., Clinical investigation of delta-9-tetrahydrocannabinol (THC) as an alternative therapy for overactive bladders in spinal cord injury (SCI) patients? Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Association for Cannabis as Medicine, 2001.

J. W. Layward-l, Cannabinoids control spasticity and tremor in a multiple sclerosis model, Nature, vol.404, pp.84-87, 2000.

U. Hagenbach, L. S. Brenneisen-r, and . Mäder-m, The treatment of spasticity with delta-9-tetrahydrocannabinol in patients with spinal cord injury International Association for Cannabis as Medicine, IACM 2nd Conference on Cannabinoids in Medicine, pp.12-13, 2003.

B. R. Egli-a, E. M. , and H. V. Spiess-y, The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with (50) Alzheimer's disease; taking the edge off with cannabinoids?, British Journal of Pharmacology, vol.152, pp.655-62, 1996.

S. R. Snider and . Consroe-p, Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia, Neurology, vol.35, issue.52, p.201, 1985.

C. J. , C. E. Pereira-a, . L. Ramos-o, . Pimentel-c, . Gagliardi-r et al., Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology, vol.2, pp.175-85, 1980.

). B. Trembly and S. M. , Double-blind clinical study of cannabidiol as a secondary anticonvulsant, Conference on Cannabis and Cannabinoids, 1990.

C. P. Sandyk-r, Potential role of cannabinoids for therapy of neurological disorders, Marijuana/Cannabinoids, Neurobiology and Neurophysiology, pp.459-524, 1992.

K. J. Greenberg and M. J. Bernsteinj, Effects of marihuana use on body weight and caloric intake in humans, Psychopharmacology, vol.49, issue.57, pp.79-84, 1976.

B. J. Olson-r, . Laubenstein-l, . P. Morales-j, . Bellman-p, . B. Yngco et al., Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS, Journal of Pain and Symptom Management, vol.10, pp.89-97, 1995.

L. Volicer, M. J. Stelly-m, L. J. Mc, and . J. Volicer-b, Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease, International Journal of Geriatric Psychiatry, vol.12, issue.9, pp.913-932, 1997.
DOI : 10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D

R. S. Hepler and . M. Frank-i, Marihuana Smoking and Intraocular Pressure, JAMA: The Journal of the American Medical Association, vol.217, issue.10, p.1392, 1971.
DOI : 10.1001/jama.1971.03190100074024

F. Grotenhermen, Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches potenzial, 2004.

T. D. Shapiro-b and L. Y. Harper-c, Effects of smoked marijuana in experimentally induced asthma, American Review of Respiratory Disease, vol.112, pp.377-86, 1975.

G. L. Bakalar-j, N. R. Sofia, and H. J. Vassar-h, Marihuana -Die verbotene Medizin Frankfurt am Main: Zweitausendeins (67) Anti-edema and analgesic properties of delta-9-tetrahydrocannabinol, Journal of Pharmacology and Experimental Therapeutics, vol.186, pp.646-55, 1973.

. Burstein-s, Das therapeutische Potenzial der ajulämischen Säure (CT3) Bern: Huber, 2001.

H. H. Erti-g, CB1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction, British Journal of Pharmacology, vol.138, pp.1251-1259, 2003.

M. F. and M. F. Steffens-s, Cannabinoid receptors in acute and chronic complications of atherosclerosis, British Journal of Pharmacology, vol.153, pp.290-298, 2008.

V. E. Mendizábal and . E. Adler-graschinsky, Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions, British Journal of Pharmacology, vol.400, issue.Suppl 1, pp.427-467, 2007.
DOI : 10.1038/sj.bjp.0707261

. I. Galve-roperh, C. M. Sanchez-c, I. M. Gomez-del-pulgar-t, and . Guzman-m, Anti-tumoral action of cannabinoids: involvement of sustained ceramide-accumulation and extracellular signal-regulated kinase activation, Nat. Med, vol.6, issue.73, pp.313-332, 2000.

J. S. Wallin-t and . J. Fowler-c, Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors, J. Pharmacol. Exp. Ther, vol.299, pp.951-959, 2001.

A. W. Cassidy, Effects of marihuana and placebo marihuana on angina pectoris, N. Engl. J. Med, vol.291, pp.65-67, 1974.

T. D. Shapiro-b and . M. Frank-i, Acute pulmonary physiologic effects of smoked marijuana and oral D9-tetrahydrocannabinol in healthy young men, N. Engl, 1973.

T. D. Shapiro-b and . M. Frank-i, Acute effects of smoked marijuana and oral D9-tetrahydrocannabinol on specific airway conductance in subjects with asthma, Am, 1974.

D. P. Tashkin, Airway effects of marijuana, cocaine, and other inhaled illicit agents, Current Opinion in Pulmonary Medicine, vol.7, issue.2, pp.43-61, 2001.
DOI : 10.1097/00063198-200103000-00001

W. C. and R. P. Kirkham-t, Hyperphagia in pre-fed rats following oral delta9-THC, Physiol. Behav, vol.65, issue.82, pp.343-346, 1998.

M. T. Greenland-s, Marijuana Use and the Risk of Lung and Upper-aerodigestive-Tract Cancers, American Journal of Epidemiology, vol.163, issue.suppl_11, pp.1829-1863, 2006.
DOI : 10.1093/aje/163.suppl_11.S108-a

D. P. Ferraro, Acute effects of marijuana on human memory and cognition, 1980.
DOI : 10.1037/e497352006-007

S. N. Hallw and . Lemon-l, The health and psychological consequences of cannabis use. Monograph series. Department of human services and health eds, p.pp, 1994.

G. R. Mcdougall-j and M. C. Marshman-j, Tolerance to marijuana-induced tachycardia in man, Acta. Pharmacol. Toxicol, vol.39, pp.65-76, 1976.

V. H. Sanchez-salvatori-m and . Medina-m, Cardiovascular effects of (-)-l 1 ?Ohdelta 8-tetrahydrocannabinol-dimethylheptyl in rats, J. Cardiovasc. Pharmacol, vol.28, pp.332-368, 1996.

F. I. Schermer-b, . Popp-r, and . Busse-r, Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists, Br. J, 1999.

. Anonyme, American psychiatric association. Diagnostic and statistical manual of mental disorders, 1994.

V. M. Vitiello-s and . Bellocchio-l, Pregnenolone Can Protect the Brain from Cannabis Intoxication, Science, vol.343, p.94, 2014.

G. E. Martineau-h, Politiques et expérimentations récentes sur les drogues aux Pays-Bas, OFDT, 2000.

G. G. Whittle-b and . J. Robson-p, The medicinal uses of cannabis et cannabinoids, 2004.